Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC cut its stake in Vir Biotechnology, Inc. (NASDAQ:VIR) by 13.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,353 shares of the company’s stock after selling 5,565 shares during the quarter. Yousif Capital Management LLC’s holdings in Vir Biotechnology were worth $356,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Signaturefd LLC lifted its stake in Vir Biotechnology by 258.5% in the 4th quarter. Signaturefd LLC now owns 3,327 shares of the company’s stock valued at $33,000 after buying an additional 2,399 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Vir Biotechnology by 96.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,448 shares of the company’s stock worth $32,000 after purchasing an additional 1,692 shares in the last quarter. Fifth Third Bancorp lifted its stake in Vir Biotechnology by 69.3% in the 3rd quarter. Fifth Third Bancorp now owns 3,941 shares of the company’s stock worth $37,000 after purchasing an additional 1,613 shares in the last quarter. Federated Hermes Inc. purchased a new position in Vir Biotechnology in the 4th quarter worth approximately $69,000. Finally, PNC Financial Services Group Inc. lifted its stake in Vir Biotechnology by 99.9% in the 3rd quarter. PNC Financial Services Group Inc. now owns 9,317 shares of the company’s stock worth $87,000 after purchasing an additional 4,656 shares in the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

VIR has been the topic of a number of research reports. JPMorgan Chase & Co. raised their target price on shares of Vir Biotechnology from $10.00 to $12.00 and gave the stock a “neutral” rating in a research note on Friday. Needham & Company LLC reissued a “buy” rating and issued a $15.00 target price on shares of Vir Biotechnology in a research note on Friday. Finally, HC Wainwright reissued a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, March 15th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.57.

Vir Biotechnology Stock Performance

VIR stock opened at $10.22 on Tuesday. The firm has a market cap of $1.37 billion, a PE ratio of -2.55 and a beta of 0.47. The firm’s 50 day moving average price is $9.79 and its 200-day moving average price is $9.61. Vir Biotechnology, Inc. has a one year low of $7.61 and a one year high of $27.48.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.51. The firm had revenue of $56.38 million for the quarter, compared to analyst estimates of $11.71 million. Vir Biotechnology had a negative net margin of 677.69% and a negative return on equity of 32.58%. The business’s revenue for the quarter was down 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.06) EPS. Equities research analysts predict that Vir Biotechnology, Inc. will post -4.04 EPS for the current fiscal year.

Insider Activity

In related news, CFO Sung Lee sold 6,008 shares of Vir Biotechnology stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $9.89, for a total value of $59,419.12. Following the completion of the sale, the chief financial officer now owns 100,492 shares in the company, valued at approximately $993,865.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Vir Biotechnology news, EVP Phillip Pang sold 3,321 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $10.24, for a total value of $34,007.04. Following the completion of the transaction, the executive vice president now owns 264,679 shares in the company, valued at $2,710,312.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Sung Lee sold 6,008 shares of the business’s stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $9.89, for a total transaction of $59,419.12. Following the completion of the transaction, the chief financial officer now owns 100,492 shares of the company’s stock, valued at approximately $993,865.88. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 152,831 shares of company stock valued at $1,525,844. 15.60% of the stock is currently owned by company insiders.

Vir Biotechnology Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.